30 results on '"Barr, E"'
Search Results
2. 448 Perception and participation in sport and exercise of peoplewith cystic fibrosis in the era of highly effective modulator therapies
3. 346 Describing genetic variation and panel detection rates for a diverse cystic fibrosis center in Georgia
4. Trigeminal Uptake and Clearance of Inhaled Manganese Chloride in Rats and Mice
5. 292: Evaluating potential differences in the disease experiences of adult minority patients with cystic fibrosis
6. High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2).
7. 150 Initiation of standardized care pathway for individuals with cystic fibrosis transmembrane conductance regulator–related metabolic syndrome at a large cystic fibrosis center.
8. A Mouse Model of Cigarette Smoke-Induced Emphysema(*)
9. SAT-163 - C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
10. SAT-139 - High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies
11. SAT-148 - C-Swift Retreatment Final Results: Highly Successful Retreatment of GT1-Infected Patients with 12 Weeks of Elbasvir/Grazoprevir plus Sofosbuvir and Ribavirin after Failure of Short-Duration All-Oral Therapy
12. SAT-128 - C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders
13. P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial
14. P0776 : Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients
15. P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection
16. P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection
17. 153 Improving consistency of examination for infants with positive newborn screening and inconclusive diagnosis.
18. (59) - Change in Body Mass Index at Listing from Primary Transplant to Re-Transplantation Predicts Re-Transplant Survival.
19. 208P Are people living with neuromuscular disorders in the north of England satisfied with National Health Service wheelchair service provision?
20. P15-08 Establishing the efficacy of the Rho-kinase inhibitor fasudil as a protective measure against wildfire smoke-induced neuroinflammation.
21. PO364 DIABETES MELLITUS PREVALENCE IN ETHNIC CHINESE AND INDIANS IN SINGAPORE AND MAURITIUS.
22. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
23. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
24. (97) - A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation
25. (839) - Pulmonary Hypertension in COPD: A Survival Analysis of Patients Listed for Lung Transplantation.
26. O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy.
27. LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease.
28. G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection.
29. O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks.
30. O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.